CH5015765

CH5015765 is an orally available Hsp90 inhibitor bound to the N-terminal ATP binding site, with a dissociation constant of 3.4 nM, CH5015765 exerts antiproliferative activity against human cancer cell lines, with IC50 values of 0.46 μM for HCT116 colorectal cancer cells and 0.57 μM for NCI-N87 gastric cancer cells. CH5015765 can be used for the study of cancer[1][2].

Product Specifications

CAS Number

[959766-47-3]

UNSPSC

12352005

Target

HSP

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.01

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

NC1=NC(C2=C(Cl)C=C3C4=C2C=CC=C4COC3)=NC(SC)=N1

Molecular Formula

C16H13ClN4OS

Molecular Weight

344.82

References & Citations

[1]Atsushi Suda, et al. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors. Bioorg Med Chem Lett. 2012 Jan 15;22 (2) :1136-41. |[2]Suda A, et al. Design and synthesis of 2-amino-6- (1H,3H-benzo[de]isochromen-6-yl) -1,3,5-triazines as novel Hsp90 inhibitors. Bioorg Med Chem. 2014 Jan 15;22 (2) :892-905.